4.7 Article

Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy

期刊

KIDNEY INTERNATIONAL
卷 91, 期 1, 页码 235-243

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.09.029

关键词

IgA nephropathy; podocytopathy; segmental sclerosis

向作者/读者索取更多资源

Focal segmental glomerulosclerosis (FSGS) is a common finding in IgA nephropathy (IgAN). Here we assessed FSGS lesions in the Oxford Classification patient cohort and correlated histology with clinical presentation and outcome to determine whether subclassification of the S score in IgAN is reproducible and of clinical value. Our subclassification of lesions in 137 individuals with segmental glomerulosclerosis or adhesion (51) identified 38% with podocyte hypertrophy, 10% with hyalinosis, 9% with resorption droplets within podocytes, 7% with tip lesions, 3% with perihilar sclerosis, and 2% with endocapillary foam cells. Reproducibility was good or excellent for tip lesions, hyalinosis, and perihilar sclerosis; moderate for podocyte hypertrophy; and poor for resorption droplets, adhesion only, and endocapillary foam cells. Podocyte hypertrophy and tip lesions were strongly associated with greater initial proteinuria. During follow-up of patients without immunosuppression, those with these features had more rapid renal function decline and worse survival from a combined event compared to S1 patients without such features and those without FSGS. Also in individuals with podocyte hypertrophy or tip lesions, immunosuppressive therapy was associated with better renal survival. In IgA nephropathy, the presence of podocyte hypertrophy or tip lesions, markers of podocyte injury, were reproducible. These features are strongly associated with proteinuria and, in untreated patients, carry a worse prognosis. Thus, our findings support reporting podocytopathic features alongside the S score of the Oxford Classification.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Transplantation

Clinical application of microRNAs in glomerular diseases

Haresh Selvaskandan, Izabella Pawluczyk, Jonathan Barratt

Summary: RNA interference (RNAi) is a widely present and important regulatory process in all organisms, modulating gene transcription and post-transcriptional processing. microRNAs (miRNAs) can regulate multiple genes within a cell, and multiple miRNAs can regulate expression of the same gene, adding complexity to gene expression regulation. miRNAs and other RNAi approaches have been used for basic science research and targeted therapeutics. This review focuses on the potential of miRNAs as biomarkers and novel therapeutics for glomerular disease.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Genetics & Heredity

Segregation analysis identifies specific alpha-defensin (DEFA1A3) SNP-CNV haplotypes in predisposition to IgA nephropathy

Nzar A. A. Shwan, Eric C. Moise, Paula E. Necsoiu, Amy J. Farr, Daniel P. Gale, Jonathan Barratt, John A. L. Armour

Summary: In this study, the researchers investigated the association between DEFA1A3 copy number variation (CNV) and IgA nephropathy. They measured DEFA1A3 copy number in UK family trios with an affected offspring and used population distributions to infer segregation in trios. The researchers observed some evidence for over- and undertransmission of specific haplotypes, but these effects were not statistically significant after correction for multiple testing.

ANNALS OF HUMAN GENETICS (2023)

Article Urology & Nephrology

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen, Andrew Stone, Daniel Cattran, Jurgen Floege, Vladimir Tesar, Hernan Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Brad H. Rovin

Summary: The clinical trial (NefIgArd) of a novel targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) demonstrated significant improvements in proteinuria and glomerular filtration rate, with good tolerability.

KIDNEY INTERNATIONAL (2023)

Article Medicine, General & Internal

Empagliflozin in Patients with Chronic Kidney Disease

William G. Herrington, Natalie Staplin, Christoph Wanner, Jennifer B. Green, Sibylle J. Hauske, Jonathan R. Emberson, David Preiss, Parminder Judge, Kaitlin J. Mayne, Sarah Y. A. Ng, Emily Sammons, Doreen Zhu, Michael Hill, Will Stevens, Karl Wallendszus, Susanne Brenner, Alfred K. Cheung, Zhi-Hong Liu, Jing Li, Lai Seong Hooi, Wen Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinya Goto, Xavier Rossello, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Dan Massey, Jens Eilbracht, Martina Brueckmann, Martin J. Landray, Colin Baigent, Richard Haynes

Summary: Empagliflozin therapy reduces the risk of disease progression or cardiovascular death in patients with chronic kidney disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Review Urology & Nephrology

An update on corticosteroid treatment for IgA nephropathy

Malak Ghaddar, Jonathan Barratt, Sean J. Barbour

Summary: The use of corticosteroids to treat IgA nephropathy has been controversial. Recent trials have shown that a reduced dose of methylprednisolone can reduce the risk of kidney damage and proteinuria in patients with IgAN. The targeted-release budesonide has also been effective in reducing short-term proteinuria. More targeted therapies with better safety profiles are being investigated.

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2023)

Letter Urology & Nephrology

The authors reply

Jonathan Barratt, Brad H. Rovin

KIDNEY INTERNATIONAL (2023)

Editorial Material Urology & Nephrology

First do no harm: systemic glucocorticoids should not be used for the treatment of progressive IgA nephropathy

Chee Kay Cheung, Jonathan Barratt

KIDNEY INTERNATIONAL (2023)

Letter Urology & Nephrology

CARD9, VAV3, and infection risk in IgA nephropathy Reply

Jonathan Barratt, Brad H. Rovin

KIDNEY INTERNATIONAL (2023)

Article Multidisciplinary Sciences

Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis

Janev Fehmi, Alexander Davies, Marilina Antonelou, Stephen Keddie, Sonja Pikkupeura, Luis Querol, Emilien Delmont, Andrea Cortese, Diego Franciotta, Staffan Persson, Jonathan Barratt, Ruth Pepper, Filipa Farinha, Anisur A. Rahman, Diana B. Canetti, Janet Gilbertson, Nigel Rendell, Aleksandar Radunovic, Thomas M. Minton, Geraint S. Fuller, Sinead R. Murphy, Aisling Carr, Mary Reilly, Filip E. Eftimov, Luuk Wieske, Charlotte Teunissen, Ian S. D. D. Roberts, Neil Ashman, Alan Salama, Simon Rinaldi

Summary: Membranous glomerulonephritis (MGN) is a common cause of nephrotic syndrome, and an association between anti-contactin-1 (CNTN1)-mediated neuropathies and MGN has been suggested. This study investigated the association between CNTN1 antibodies and clinical features of patients with immune-mediated neuropathies and MGN. It was found that CNTN1 antibodies were present in patients with immune-mediated neuropathy and concurrent MGN, and CNTN1-containing immune complexes were found in the renal glomeruli of these patients, suggesting CNTN1 as a common target for autoantibody-mediated pathology in MGN.

PLOS ONE (2023)

Article Multidisciplinary Sciences

Polynucleotide phosphorylase protects against renal tubular injury via blocking mt-dsRNA-PKR-eIF2α axis

Yujie Zhu, Mingchao Zhang, Weiran Wang, Shuang Qu, Minghui Liu, Weiwei Rong, Wenwen Yang, Hongwei Liang, Caihong Zeng, Xiaodong Zhu, Limin Li, Zhihong Liu, Ke Zen

Summary: Reduction of renal tubular cell PNPT1 causes renal tubular translation arrest and atrophy, which leads to tubular injury. Increasing PNPT1 expression can alleviate tubular injury.

NATURE COMMUNICATIONS (2023)

Article Urology & Nephrology

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E. Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hiddo J. L. Heerspink, Alex Mercer, Irene L. Noronha, Jai Radhakrishnan, Michelle N. Rheault, William Rote, Howard Trachtman, Hernan Trimarch, Vlado Perkovic, PROTECT Investigators

Summary: The PROTECT trial is a multicenter, international study evaluating the efficacy and safety of sparsentan versus irbesartan in IgA nephropathy patients. Baseline characteristics of enrolled patients are described and compared to other relevant studies. The results will provide important characterization of the treatment effect in IgA nephropathy patients at high risk of kidney failure.

KIDNEY INTERNATIONAL REPORTS (2023)

Article Urology & Nephrology

Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis

Daisuke Koya, Stefan D. Anker, Luis M. Ruilope, Peter Rossing, Zhihong Liu, Byung Wan Lee, Chien-Te Lee, Charlie Scott, Peter Kolkhof, Robert Lawatscheck, Lili Wang, Amer Joseph, Bertram Pitt

Summary: This study found that finerenone significantly improved cardiorenal outcomes in Asian patients, with similar benefits seen in non-Asian patients as well. The safety profile of finerenone was consistent across subgroups.

AMERICAN JOURNAL OF NEPHROLOGY (2023)

Article Medicine, General & Internal

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, Stewart Bieler, Pietro Canetta, Dong-Wan Chae, Gaia Coppock, Ulysses Diva, Loreto Gesualdo, Hiddo J. L. Heerspink, Jula K. Inrig, Gianna M. Kirsztajn, Donald Kohan, Radko Komers, Laura A. Kooienga, Kenneth Lieberman, Alex Mercer, Irene L. Noronha, Vlado Perkovic, Jai Radhakrishnan, William Rote, Brad Rovin, Vladimir Tesar, Hernan Trimarchi, James Tumlin, Muh Geot Wong, Howard Trachtman, DUPRO Steering Comm, DUPLEX Investigators

Summary: In the treatment of FSGS, sparsentan showed a better reduction in proteinuria compared to irbesartan. However, there were no significant differences in eGFR slope between the two groups at 108 weeks. Both sparsentan and irbesartan demonstrated similar safety profiles.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Pharmacology & Pharmacy

Conditional power and information fraction calculations at an interim analysis for random coefficient models

Sandra A. Lewis, Kevin J. Carroll, Todd Devries, Jonathan Barratt

Summary: Random coefficient (RC) models are commonly used in clinical trials to estimate the rate of change over time in longitudinal data. This paper provides calculation methods, with practical examples, for determining conditional power (CP) at an interim analysis for a RC model with longitudinal data.

PHARMACEUTICAL STATISTICS (2023)

Meeting Abstract Urology & Nephrology

PROTEINURIA AND DISEASE PROGRESSION IN THE RADAR IGAN COHORT

David Pitcher, Fiona Braddon, Bruce Hendry, Alex Mercer, Kate Osmaston, Moina Saleem, Retha Steenkamp, A. Neil Turner, Kaijun Wang, Jonathan Barratt, Daniel Gale

AMERICAN JOURNAL OF KIDNEY DISEASES (2023)

暂无数据